TOP > 外国特許検索 > AGENT FOR TREATING, PREVENTING OR IMPROVING PSYCHIATRIC AND NERVOUS SYSTEM DISORDERS OR SYMPTOMS

AGENT FOR TREATING, PREVENTING OR IMPROVING PSYCHIATRIC AND NERVOUS SYSTEM DISORDERS OR SYMPTOMS

外国特許コード F210010364
整理番号 (S2019-0576-N0)
掲載日 2021年4月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP036336
国際公開番号 WO 2021015300
国際出願日 令和2年9月25日(2020.9.25)
国際公開日 令和3年1月28日(2021.1.28)
優先権データ
  • 特願2019-136756 (2019.7.25) JP
発明の名称 (英語) AGENT FOR TREATING, PREVENTING OR IMPROVING PSYCHIATRIC AND NERVOUS SYSTEM DISORDERS OR SYMPTOMS
発明の概要(英語) Disclosed is a novel means that is effective in treating etc. psychiatric and nervous system disorders and symptoms such as anxiety and depression, and that is highly stable and unlikely to cause problems of dependency and side effects. The agent provided by the present invention, which treats, prevents or improves psychiatric and nervous system disorders or symptoms, contains any of the following as active ingredients: (1) disulfiram; (2) a metallic complex of diethyldithiocarbamate; (3) a disulfide capable of generating diethyldithiocarbamate in vivo; (4) a pharmaceutically-acceptable salt of (1), (2) or (3); and (5) a solvate of (1), (2), (3) or (4).
従来技術、競合技術の概要(英語) BACKGROUND ART
Anxiety agents and depressants are often used in medications for psychological diseases associated with anxiety disorders and depressive disorders. Various anxiolytic agents and antidepressants have been developed that have low dependency and low side effects in order to withstand long-term administration. however, the problems of dependency and side effects remain significant problems with anxiolytic agents and antidepressants.
Disulfiram has aldehyde dehydrogenase inhibitory activity, which suppresses ethanol metabolism in the liver and causes acetaldehyde to accumulate in the body, which causes death. Thus, taking disulfide results in symptoms of adverse sickness even with small amounts of alcohol. Utilizing this effect, disulfiram is used as an anti-alcoholic agent against chronic alcohol poisoning. In addition to this effect, disulfiram is known to exert an anti-cancer effect by an effect of inducing death of cancer cells or cancer stem cells themselves (for example, Non-Patent Document 1 ~ 3 and Patent Document 1), and to exert an anti-cancer effect and an anti-inflammatory effect by an effect of regulating constituent cells of a microenvironment in cancer and inflammation (Patent Document 2).
However, disulfiram is not known to have any effect of treating, preventing, or ameliorating mental or neurological symptoms such as anxiety symptoms or depressive symptoms. On the other hand, disulfiram has been reported to cause psychiatric disorders such as anxiety (NpL 4 ~ 6). Also in the package insert (Non-Patent Document 7) of the anti-alcoholism agent "knockbin" containing disulfiram as an active ingredient, depression, emotional instability, hallucinations, confusion, etc. as side effects that occur in the psychiatric nervous system, depression, emotional instability, hallucinations, confusion, Delirium and the like (sometimes due to the cessation of alcohols), headaches, dizziness, tinnitus, drowsiness, and sleep disorders are mentioned, but there is no mention of any effect of treating, preventing, or ameliorating psychotic or neurological symptoms such as anxiety, depression, and sleep disorders.
Patent Document 3 describes the use of disulfiums for mild cognitive impairment (MCI) or Alzheimer's disease. However, according to the data described in the Examples, disulfiram promoted secretion of sAPPα from cells transfected with wild type APP in in vitro experiments with cultured cells; Cerebrovascular barrier penetration of disulfiram is very low in brain uptake studies using mouse biology, and experiments of administering to Alzheimer's model mice to measure changes in Alzheimer's biomarkers show only results with compounds other than disulfiram. Therefore, Patent Document 3 does not disclose that disulfiram has an effect of treating or preventing MCI or Alzheimer's disease.
Database ClinicalTrials.gov (https://clinicaltrials.gov /) of clinical trial information includes ClinicalTrials.gov Identifier: As NCT03469128, a clinical trial has been registered in which disulfiram is administered to patients with concurrent posttraumatic stress disorder (PTSD) and substance usage disorder (SUD) (Non-Patent Document 11). Although the latest update was March 19, 2018 and the Recruitment Status was Completed, clinical trial results were not enrolled and there is no disclosure that significant effect was observed in the disulfide groups. In addition, as ClinicalTrials.gov Identifier: NCT03212599, a test has been registered for the expression of ADAM10 by real-time RT-PCR using blood samples collected before and 2 weeks after administration of disulfiram from alcohol poisoning patients (Non-Patent Document 12). Study Description of NCT03212599 describes that ADAM10 is a promising target of amyloid beta peptide prevention strategies, and that treatment of human neurons with disulfiram is known to increase the expression of ADAM10, indicating that disulfiram may have a neuroprotective effect. This study, however, also does not disclose that the most recent update was July 24, 2017, the Recruitment Status was Completed, but the results of the study were not enrolled and disulfiram significantly increased the expression of ADAM10 in the blood.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO UNIVERSITY OF SCIENCE FOUNDATION
  • 発明者(英語)
  • SAITOH, Akiyoshi
  • TERASHIMA, Yuya
  • MATSUSHIMA, Kouji
  • SANO, Yoshitake
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS IT JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close